APLT Logo

Applied Therapeutics, Inc. (APLT) 

NASDAQ
Market Cap
$509.63M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
296 of 809
Rank in Industry
173 of 445

Largest Insider Buys in Sector

APLT Stock Price History Chart

APLT Stock Performance

About Applied Therapeutics, Inc.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Insider Activity of Applied Therapeutics, Inc.

Over the last 12 months, insiders at Applied Therapeutics, Inc. have bought $65,367 and sold $6.17M worth of Applied Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Applied Therapeutics, Inc. have bought $656,228 and sold $7.75M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Kanter Stacy J. (director) — $65,367.

The last purchase of 30,000 shares for transaction amount of $65,367 was made by Kanter Stacy J. (director) on 2023‑12‑01.

List of Insider Buy and Sell Transactions, Applied Therapeutics, Inc.

2024-06-06SaleShendelman ShoshanaPresident and CEO
61,795
0.0519%
$4.32$266,954+5.56%
2024-06-06SalePerfetti RiccardoChief Medical Officer
22,003
0.0185%
$4.32$95,053+5.56%
2024-06-06SaleFuntleyder Leslie D.Chief Financial Officer
16,980
0.0143%
$4.32$73,354+5.56%
2024-06-05SaleALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner
150,000
0.1261%
$4.24$636,000+5.66%
2024-06-04SaleALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner
150,000
0.131%
$4.21$631,500+10.45%
2024-03-14SaleShendelman ShoshanaPresident and CEO
318,573
0.2652%
$5.39$1.72M-20.15%
2024-03-14SalePerfetti RiccardoChief Medical Officer
110,804
0.0922%
$5.39$597,234-20.15%
2024-03-14SaleHansard AdamChief Commercial Officer
48,871
0.0407%
$5.39$263,415-20.15%
2024-03-14SaleFuntleyder Leslie D.Chief Financial Officer
28,727
0.0239%
$5.39$154,839-20.15%
2023-12-01PurchaseKanter Stacy J.director
30,000
0.0358%
$2.18$65,367+82.78%
2023-11-30SaleShendelman ShoshanaPresident and CEO
3,968
0.0048%
$1.97$7,817+111.54%
2023-11-30SalePerfetti RiccardoChief Medical Officer
1,583
0.0019%
$1.97$3,119+111.54%
2023-11-30SaleHansard AdamChief Commercial Officer
965
0.0012%
$1.97$1,901+111.54%
2023-11-03SaleALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner
143,450
0.2215%
$2.31$331,370+78.90%
2023-11-02SaleALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner
103,808
0.1662%
$2.32$240,835+83.33%
2023-11-01SaleALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner
172,742
0.2742%
$2.36$407,671+82.33%
2023-10-31SaleALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner
155,000
0.2466%
$2.41$373,550+75.83%
2023-09-27SaleShendelman ShoshanaPresident and CEO
115,632
0.1873%
$2.70$312,206+30.68%
2023-09-27SalePerfetti RiccardoChief Medical Officer
10,932
0.0177%
$2.70$29,516+30.68%
2023-09-27SaleHansard AdamChief Commercial Officer
9,720
0.0157%
$2.70$26,244+30.68%

Insider Historical Profitability

10.44%
ALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner
5855077
7.2253%
$4.4626+18.45%
Shendelman ShoshanaPresident and CEO
3756019
3.3619%
$4.46612+32.1%
Perfetti RiccardoChief Medical Officer
1009534
0.8965%
$4.46158<0.0001%
Hansard AdamChief Commercial Officer
732919
0.4944%
$4.4605
Kanter Stacy J.director
63000
0.0816%
$4.4630<0.0001%
Funtleyder Leslie D.director
291441
0.0222%
$4.46019
MARCUS JOEL Sdirector
365360
0.4731%
$4.4623+10.6%
Silberstein CharlesChief Financial Officer
87803
0.1137%
$4.4601
Mahadevan ChidsSee Remarks
9800
0.0127%
$4.4601

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Franklin Templeton Investments$71.84M9.2410.56M+50.53%+$24.12M0.02
Vr Adviser Llc$61.71M7.949.07M+45.2%+$19.21M3
Perceptive Advisors$54.43M7.018.01M+96.19%+$26.69M0.04
Janus Henderson$43.56M5.616.41M+198.57%+$28.97M0.02
Tupelo Capital Management LLC$37.91M4.885.57M+1.83%+$679,999.9924.79
Morgan Stanley$21.72M2.83.19M+5,856.5%+$21.35M<0.01
The Vanguard Group$20.47M2.633.01M-6.82%-$1.5M<0.0001
Simplify Asset Management Inc$19.16M2.472.82M+16.55%+$2.72M1.84
Adage Capital Partners Gp L L C$18.02M2.322.65MNew+$18.02M0.03
Tang Capital Management, LLC$15.16M1.952.23MNew+$15.16M0.06
Frazier Life Sciences Management L P$13.28M1.711.95MNew+$13.28M0.68
Parkman Healthcare Partners Llc$12.61M1.621.85M+81.99%+$5.68M1.56
Schonfeld Group$12.49M1.611.84M+273.69%+$9.15M0.09
Opaleye Management Inc$3.66M1.551.77M+62.01%+$1.4M0.58
Soleus Capital Management, L.P.$10.64M1.371.56M+239.61%+$7.51M0.1
ROCK SPRINGS CAPITAL MANAGEMENT, LP$10.19M1.311.5M+67.33%+$4.1M0.26
Laurion Capital Management LP$10.07M1.31.48M+243.62%+$7.14M0.28
Alyeska Investment Group L P$9.77M1.261.44M-44.6%-$7.87M0.06
Logos Global Management Lp$8.98M1.181.35M-18.68%-$2.06M0.96
Artal Group S A$6.86M0.881.01MNew+$6.86M0.04
BlackRock$6.73M0.87989,277+87.4%+$3.14M<0.0001
Millennium Management LLC$6.3M0.81926,425+54.39%+$2.22M<0.01
ACUTA CAPITAL PARTNERS LLC$5.39M0.69792,000+50.83%+$1.81M3.5
Goldman Sachs$4.86M0.63715,208+4,169.39%+$4.75M<0.01
Deutsche Bank$4.23M0.55622,227New+$4.23M<0.01
Sphera Fund$4.21M0.54619,029New+$4.21M0.7
Geode Capital Management$4.11M0.53604,428+4.63%+$182,001.81<0.0001
Invesco$3.67M0.47539,857New+$3.67M<0.01
Susquehanna International Group$3.3M0.42484,885-14.55%-$561,408.00<0.01
Qube Research & Technologies$3.12M0.4459,141+137.07%+$1.81M<0.01
Walleye Capital$2.1M0.27308,316+1,713.62%+$1.98M0.01
Jane Street Capital$1.66M0.21244,612+85.44%+$766,400.52<0.01
State Street$1.41M0.18206,669+46.92%+$448,799.94<0.0001
Squarepoint Ops LLC$1.32M0.17193,758+1,292.44%+$1.22M0.01
JPMorgan Chase$1.22M0.16178,924+281.23%+$897,538.65<0.0001
Renaissance Technologies$1.2M0.15175,800-73.08%-$3.24M<0.01
Bridgeway Capital Management$1.18M0.15173,800-10.32%-$136,000.000.02
Cubist Systematic Strategies$1.11M0.14163,072+178.29%+$710,430.260.01
Two Sigma$1.06M0.14155,158-45.75%-$889,704.86<0.01
Man Group Plc$1.05M0.14154,636-7.15%-$81,015.21<0.01
UBS$1.04M0.13152,760+27.08%+$221,360.19<0.0001
Rockefeller Capital Management L P$1.02M0.13150,000New+$1.02M<0.01
J. Goldman & Company$995,466.000.13146,392New+$995,466.000.05
Citigroup$807,867.000.1118,804-45.98%-$687,629.43<0.01
Northern Trust$723,880.000.09106,453-0.14%-$979.20<0.0001
Hrt Financial Llc$672,000.000.0998,879New+$672,000.00<0.01
Eam Investors$631,530.000.0892,872-49.21%-$611,986.790.1
OMERS$439,960.000.0664,700+393.89%+$350,880.000.01
Barclays$417,000.000.0561,272New+$417,000.00<0.0001
Richmond Brothers, Inc.$420,424.000.0561,827-50%-$420,424.000.78